William Blair Has Positive Outlook for ADPT Q3 Earnings

Key Points

• William Blair has increased their Q3 2025 earnings estimates for Adaptive Biotechnologies, projecting earnings per share of ($0.09), an improvement from their previous estimate of ($0.20).
• The company reported $49.94 million in revenue for their last quarter, surpassing analyst expectations, with a year-over-year revenue growth of 36.3%.
• Analysts have a consensus rating of “Moderate Buy” for Adaptive Biotechnologies, with a target price of $12.38, supported by several recent upgrades from various firms.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Free Report) - Research analysts at William Blair lifted their Q3 2025 earnings estimates for Adaptive Biotechnologies in a report released on Monday, August 18th. William Blair analyst A. Brackmann now forecasts that the company will post earnings per share of ($0.09) for the quarter, up from their previous estimate of ($0.20). The consensus estimate for Adaptive Biotechnologies' current full-year earnings is ($0.92) per share. William Blair also issued estimates for Adaptive Biotechnologies' Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.56) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.66) EPS.

A number of other brokerages have also recently weighed in on ADPT. JPMorgan Chase & Co. lifted their price target on shares of Adaptive Biotechnologies from $10.00 to $14.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. TD Cowen lifted their price target on shares of Adaptive Biotechnologies from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Wednesday, August 6th. Craig Hallum initiated coverage on shares of Adaptive Biotechnologies in a research report on Wednesday, June 18th. They set a "buy" rating and a $15.00 price target on the stock. Piper Sandler boosted their target price on shares of Adaptive Biotechnologies from $13.00 to $15.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Finally, The Goldman Sachs Group boosted their target price on shares of Adaptive Biotechnologies from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $12.38.

Adaptive Biotechnologies Price Performance

ADPT stock traded up $0.12 during midday trading on Thursday, reaching $12.79. 272,668 shares of the company's stock traded hands, compared to its average volume of 2,022,900. The company has a market capitalization of $1.95 billion, a P/E ratio of -15.60 and a beta of 1.92. Adaptive Biotechnologies has a fifty-two week low of $3.98 and a fifty-two week high of $13.40. The business has a 50-day moving average price of $11.47 and a two-hundred day moving average price of $9.48.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.07. The firm had revenue of $49.94 million for the quarter, compared to analysts' expectations of $49.40 million. Adaptive Biotechnologies had a negative net margin of 59.07% and a negative return on equity of 60.93%. Adaptive Biotechnologies's revenue was up 36.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.31) earnings per share.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Bridgefront Capital LLC acquired a new stake in Adaptive Biotechnologies in the fourth quarter valued at $80,000. Personal CFO Solutions LLC acquired a new stake in Adaptive Biotechnologies in the first quarter valued at $84,000. Blair William & Co. IL acquired a new stake in Adaptive Biotechnologies in the first quarter valued at $84,000. Wealth Enhancement Advisory Services LLC acquired a new stake in Adaptive Biotechnologies in the first quarter valued at $87,000. Finally, Candriam S.C.A. acquired a new stake in Adaptive Biotechnologies in the first quarter valued at $90,000. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.